-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Downgrades Silence Therapeutics to Neutral, Lowers Price Target to $20

Benzinga·10/21/2026 11:50:02
Diffusion vocale
HC Wainwright & Co. analyst Patrick R. Trucchio downgrades Silence Therapeutics (NASDAQ:SLN) from Buy to Neutral and lowers the price target from $75 to $20.